MRM Health NV, a clinical-stage biopharmaceutical company specializing in microbiome-based therapeutics for inflammatory diseases and immune-oncology, proudly announced the completion of a €55 million (US$64 million) Series B financing round.

“Our CORAL® platform gives us a unique edge in designing potent, resilient and scalable microbiome-based therapeutics. This new funding will allow us to further build both our platform and pipeline," said Sam Possemiers, CEO of MRM Health.

The financing round was spearheaded by the French pharmaceutical group Biocodex, with significant participation from German-based ATHOS, along with new investor BNP Paribas Fortis Private Equity and existing investors SFPIM, Ackermans & van Haaren (AvH), OMX Europe Venture Fund (OMX), Qbic II, and VIB.

The funds raised will facilitate MRM Health in completing a Phase 2b clinical trial for its lead program MH002, which targets patients suffering from mild-to-moderate ulcerative colitis. MH002 stands as the most advanced Live Biotherapeutic Product (LBP) developed from a rationally designed combination of disease-specific bacteria, with promising clinical data from Phase 2a trials indicating safety and initial efficacy in both mild-to-moderate ulcerative colitis and the orphan disease indication pouchitis.

Further, the company aims to progress two innovative microbial consortia programs to IND approval, focusing on inflammation and enhanced efficacy of immune-oncology therapies. MRM Health is also set to broaden its portfolio of LBPs through strategic partnerships in both human and animal health sectors.

In conjunction with the financing, MRM Health and Biocodex plan to forge a strategic collaboration aimed at developing novel therapeutic assets and scalable manufacturing capabilities for LBPs. This partnership is expected to yield substantial additional non-dilutive funding over the coming years, thus reinforcing the operational foundation of MRM Health.

“This funding marks a pivotal moment for MRM Health,” commented Sam Possemiers. “With the support of our experienced international investor syndicate, we are now well positioned to deliver transformative therapies for patients with chronic inflammatory diseases, where current treatments often fall short. Our CORAL® platform gives us a unique edge in designing potent, resilient and scalable microbiome-based therapeutics. This new funding will allow us to further build both our platform and pipeline.”

“Biocodex is a pioneer in microbiota science for over 70 years,” stated Nicolas Coudurier, CEO of Biocodex. “We are excited to support MRM Health’s unique platform approach and leadership role in the field, reflecting our strategy of fostering innovation rooted in our core expertise. By combining our long-standing leadership in microbiota with breakthrough live biotherapeutics platforms, we aim to deliver meaningful solutions for patients, worldwide.”

“MRM Health is at the forefront of a new era in microbiome-based therapeutics,” said Julian Zachmann from ATHOS. “Their technology has reached the maturity needed to effectively develop, scale and commercialize live biotherapeutics for major chronic inflammatory diseases with high unmet need. We are proud to support their journey toward significant patient impact.”

“BNP Paribas Fortis Private Equity is delighted to join a strong syndicate of investors to support the further development of MRM Health," expressed Raf Moons, Head of BNP Paribas Fortis Private Equity. “With two decades of unique scientific expertise in the field of microbiome, this funding round reflects our confidence in MRM Health’s technology and the management’s ability to translate science into therapeutic solutions that will truly make a difference for patients.”

“We warmly welcome our new investors and thank them for their trust,” remarked Werner Cautreels, Chairman of MRM Health Board of Directors. “With this strong international syndicate, MRM Health is well equipped to advance its pipeline and deliver this novel class of therapeutics to patients in need of alternative, innovative treatment options.”

As part of the Series B financing, Jean-Patrick Hennebelle (Biocodex), Julian Zachmann (ATHOS), and Goedele Ertveldt (SFPIM) will join MRM Health’s Board of Directors.
‍